Microbot Medical Inc. (MBOT) Analyst Forecast
Revenue and earnings estimates published by analysts covering Microbot Medical Inc. (MBOT), and the range of their price targets. Everything on this page is a forecast made by other people — DeltaScreener does not produce estimates or targets of its own.
For Microbot Medical Inc., analysts forecast revenue rising from $23.77T in 2023 to $48.20T in 2029; the average estimate for 2029 earnings per share is $-0.09; with published estimates ranging from $-0.12 to $-0.07; 3 analysts contribute to these figures. These are forecasts published by analysts, not results.
Analyst price targets
A price target is one analyst's forecast of where a share might trade, usually over twelve months. Targets are frequently revised, they disagree with each other, and they are not a measure of what a company is worth.
Revenue forecast (USD millions)
The spread between low and high is how far analysts disagree, which is usually a better guide than the average alone.
Earnings per share forecast
Microbot Medical Inc. (MBOT) forecast — frequently asked questions
What is the analyst price target for Microbot Medical Inc.?
Analysts covering Microbot Medical Inc. (MBOT) have a consensus price target of $3.25, 235.1% above the current price of $0.97. Published targets range from $2.50 to $4.00. A price target is a forecast, not a measure of value, and targets are revised often.
What are analysts forecasting for Microbot Medical Inc.'s earnings?
The average analyst estimate for Microbot Medical Inc. (MBOT) earnings per share in 2029 is -0.09, with individual estimates between -0.12 and -0.07.
How much revenue is Microbot Medical Inc. expected to make?
Analysts forecast Microbot Medical Inc. (MBOT) revenue of $48.20T in 2029, based on 1 published estimates.
How many analysts cover MBOT?
3 analysts contribute estimates for Microbot Medical Inc. (MBOT). Thin coverage makes an average less reliable.
Popular Stocks
Related stock screens
Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.